<DOC>
	<DOCNO>NCT00749697</DOCNO>
	<brief_summary>The main purpose study establish relationship administered activity radioiodine absorb dose tumor site .</brief_summary>
	<brief_title>Radioiodine Dosimetry Protocol Thyroid Cancer Metastases</brief_title>
	<detailed_description>Study Design - assessment patient multiple tumour site metastatic thyroid cancer correlate administer activity absorb dose . Patients receive standard therapy dose 5.5 GBq per hospital policy change protocol purpose .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<criteria>age 18 histological confirmation differentiate thyroid carcinoma available WHO performance score 02 metastatic site lung and/or bone and/or nodal ( radiologically measurable disease &gt; 1 cm ) life expectancy &gt; 6 month patient undergone total/near total thyroidectomy past history sensitivity/reaction 1311 non iodine concentrating tumour receive chemotherapy radiotherapy 6 week pregnant breast feed patient iodine contrast injection last 3 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>radioiodine</keyword>
	<keyword>differentiate thyroid cancer</keyword>
	<keyword>dosimetry</keyword>
	<keyword>metastasis</keyword>
</DOC>